全文获取类型
收费全文 | 1642565篇 |
免费 | 111258篇 |
国内免费 | 2568篇 |
专业分类
耳鼻咽喉 | 22712篇 |
儿科学 | 53316篇 |
妇产科学 | 43175篇 |
基础医学 | 242858篇 |
口腔科学 | 46104篇 |
临床医学 | 147908篇 |
内科学 | 309030篇 |
皮肤病学 | 37437篇 |
神经病学 | 121642篇 |
特种医学 | 63269篇 |
外国民族医学 | 276篇 |
外科学 | 246553篇 |
综合类 | 33860篇 |
现状与发展 | 3篇 |
一般理论 | 404篇 |
预防医学 | 117922篇 |
眼科学 | 38338篇 |
药学 | 129270篇 |
10篇 | |
中国医学 | 4709篇 |
肿瘤学 | 97595篇 |
出版年
2019年 | 12230篇 |
2018年 | 17621篇 |
2017年 | 13781篇 |
2016年 | 15494篇 |
2015年 | 17277篇 |
2014年 | 23589篇 |
2013年 | 34928篇 |
2012年 | 47282篇 |
2011年 | 49916篇 |
2010年 | 29348篇 |
2009年 | 27634篇 |
2008年 | 46213篇 |
2007年 | 49584篇 |
2006年 | 50454篇 |
2005年 | 47624篇 |
2004年 | 45980篇 |
2003年 | 44054篇 |
2002年 | 42633篇 |
2001年 | 86424篇 |
2000年 | 88320篇 |
1999年 | 73423篇 |
1998年 | 18767篇 |
1997年 | 16320篇 |
1996年 | 16515篇 |
1995年 | 15627篇 |
1994年 | 14183篇 |
1993年 | 13361篇 |
1992年 | 55330篇 |
1991年 | 54050篇 |
1990年 | 52987篇 |
1989年 | 51409篇 |
1988年 | 46514篇 |
1987年 | 45268篇 |
1986年 | 42861篇 |
1985年 | 40211篇 |
1984年 | 29371篇 |
1983年 | 24846篇 |
1982年 | 13762篇 |
1979年 | 26563篇 |
1978年 | 18242篇 |
1977年 | 15951篇 |
1976年 | 14402篇 |
1975年 | 16281篇 |
1974年 | 18970篇 |
1973年 | 18289篇 |
1972年 | 17382篇 |
1971年 | 16272篇 |
1970年 | 15234篇 |
1969年 | 14443篇 |
1968年 | 12971篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
121.
Willemijn A K M Windt Atsua Tahara Alex C A Kluppel Dick de Zeeuw Robert H Henning Richard P E van Dokkum 《Journal of the renin-angiotensin-aldosterone system》2006,7(4):217-224
INTRODUCTION: Vasopressin, mainly through the V1a-receptor, is thought to be a major player in the maintenance of hyperfiltration. Its inhibition could therefore lead to a decrease in progression of chronic renal failure. To this end, the effect of the vasopressin V1a-receptor-selective antagonist, YM218, was studied on proteinuria and focal glomerulosclerosis in early and late intervention after 5/6 nephrectomy in rats, and compared with an angiotensin-converting enzyme inhibitor (ACE-I). MATERIALS AND METHODS: After 5/6 nephrectomy, early intervention was performed between week 2 and 10 thereafter with the V1a-receptor-selective antagonist (VRA, 10 mg/kg/day, n=10), enalapril (ACE-I, 10 mg/kg/day, n=9), or vehicle (n=8). Late intervention was performed in another group between week 6 and 12 with VRA (10 mg/kg/day, n=7), lisinopril (ACE-I, 5 mg/kg/day, n=7), or vehicle (n=7). RESULTS: In early intervention, proteinuria and focal glomerulosclerosis were significantly decreased by VRA compared to vehicle (44+7% and 59+8% respectively). ACE-I significantly decreased proteinuria (67+7%) and a trend towards a decrease in focal glomerulosclerosis was observed (30+18%). In late intervention, VRA did not decrease proteinuria and focal glomerulosclerosis compared to vehicle (21+20% and 0%, respectively), ACE-I significantly lowered proteinuria (92+2%) and a focal glomerulosclerosis (69+1%) lowering trend was observed. CONCLUSION: These results indicate that VRA may protect against early progression of renal injury after 5/6 nephrectomy, whereas its effectiveness seems limited in established renal damage. 相似文献
122.
123.
124.
125.
Both vascular surgery and endovascular interventions traumatise the arterial wall, especially the endothelium. The vessel responds with neointimal hyperplasia and/or constrictive remodelling, and this is still the limiting factor in curative interventions. Stent placement prevents constrictive remodelling but is the main trigger for in-stent restenosis. Hyperproliferation of neointimal tissue is the main response to arterial thrombosis, local inflammation or medio-intimal injury such as occurs, for example, after balloon dilatation in the region of arterial anastomoses or of a thrombectomy (Fogarty-manoeuvre). At present, research on prevention of restenosis is focused on inhibiting neointimal hyperproliferation by using drug-eluting stents, and especially sirolimus- or paclitaxel-eluting stents. In addition, further experimental research work is in progress, with the aim of esablishing new treatment regimens and solving the problem of neointimal formation, thrombosis and constrictive remodelling. These include both local and systemic pharmacological therapy, brachy- and laser therapy, and many genetic treatment options, some of which are currently the subjects of experimental studies and early-stage clinical trials. Gene therapy seems like a promising way of preventing restenosis, but has not yet been tested in clinical trials. In the near future, selective, simultaneous, and perhaps even polyphasic regulation for gene silencing of two or more genes involved in the development of restenosis could improve the long-term patency rate. 相似文献
126.
127.
128.
129.
N Jastrow E Antonelli R Robyr O Irion M Boulvain 《Ultrasound in obstetrics & gynecology》2006,27(4):420-424
OBJECTIVE: To evaluate the reproducibility of sonographic measurement of the lower uterine segment in pregnant women at term. METHODS: Two independent observers performed transabdominal sonography on 129 women between 36 and 38 weeks of gestation who had had a previous Cesarean section. Sonography was performed when the patients had a full and a half-full bladder; in 100 patients, the measurements were also performed transvaginally, with the patients having an empty bladder. Agreement was quantified by the intraclass correlation coefficient and, using a cut-off of 3.5 mm, by the kappa coefficient. RESULTS: The intraobserver agreement was generally high (intraclass correlation coefficient > 0.90). The interobserver agreement was higher on transvaginal (intraclass correlation coefficient, 0.94) compared with transabdominal (0.70 and 0.84, with full and half-full bladder, respectively) ultrasound. The kappa coefficient was 0.75 transvaginally, compared with 0.34 and 0.54 using the transabdominal approach, with full and half-full bladder, respectively. CONCLUSION: The agreement between two observers for sonographic transvaginal measurement of the lower uterine segment can be considered good, compared with poor to moderate agreement using the transabdominal approach. 相似文献
130.
A Sharma H L Goh N Asokananthan A Bakker G A Stewart H W Mitchell 《The European respiratory journal》2006,27(1):20-28
Mucosal trypsin, a protease-activated receptor (PAR) stimulant, may have an endogenous bronchoprotective role on airway smooth muscle. To test this possibility the effects of lumenal trypsin on airway tone in segments of pig bronchus were tested. Bronchial segments from pigs were mounted in an organ chamber containing Kreb's solution. Contractions were assessed from isovolumetric lumen pressure induced by acetylcholine (ACh) or carbachol added to the adventitia. Trypsin, added to the airway lumen (300 microg x mL(-1)), had no immediate effect on smooth muscle tone but suppressed ACh-induced contractions after 60 min, for at least 3 h. Synthetic activating peptides (AP) for PAR1, PAR2 or PAR3 were without effect, but PAR4 AP caused rapid, weak suppression of contractions. Lumenal thrombin was without effect and did not prevent the effects of trypsin. Effects of trypsin were reduced by N(omega)-nitro-L-arginine methyl ester but not indomethacin. Trypsin, thrombin and PAR4 AP released prostaglandin E2. Adventitially, trypsin, thrombin and PAR4 AP (but not PAR2 AP) relaxed carbachol-toned airways after <3 min. The findings of this study show that trypsin causes delayed and persistent bronchoprotection by interacting with airway cells accessible from the lumen. The signalling mechanism may involve nitric oxide synthase but not prostanoids or protease-activated receptors. 相似文献